Hans Hendriks

List of Publications by Year
in descending order

31	1,101	394421 19	434195 31
papers	citations	h-index	g-index

32	32	32	1393
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell, 1995, 83, 105-120.	2.0	131
2	EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer, 1993, 29, 897-906.	2.8	112
3	High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Annals of Oncology, 1999, 10, 1233-1240.	1.2	90
4	Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochemical Pharmacology, 2004, 67, 503-511.	4.4	81
5	Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Investigational New Drugs, 2011, 29, 456-466.	2.6	76
6	EO9 (Apaziquone): from the clinic to the laboratory and back again. British Journal of Pharmacology, 2013, 168, 11-18.	5.4	67
7	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	1.8	63
8	Depletion of macrophages and disappearance of postcapillary high endothelial venules in lymph nodes deprived of afferent lymphatic vessels. Cell and Tissue Research, 1980, 211, 375-89.	2.9	57
9	Innovation in oncology clinical trial design. Cancer Treatment Reviews, 2019, 74, 15-20.	7.7	41
10	KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells. Clinical Cancer Research, 2008, 14, 4593-4602.	7.0	39
11	Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. General Pharmacology, 1996, 27, 421-429.	0.7	34
12	A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues. European Journal of Medicinal Chemistry, 1992, 27, 825-833.	5.5	32
13	The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. European Journal of Cancer, 1998, 34, 1602-1606.	2.8	30
14	Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Arabinosylcytosine (araâ€€) in Leukemia and Solid Tumor Cell Lines. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1523-1526.	1.1	29
15	Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1329-1333.	1.1	28
16	Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. European Journal of Cancer, 1995, 31, 356-361.	2.8	27
17	Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. European Journal of Cancer, 1999, 35, 1143-1149.	2.8	23
18	Alkyl and Alkoxyethyl Antineoplastic Phospholipids. Journal of Medicinal Chemistry, 1996, 39, 2609-2614.	6.4	21

#	Article	IF	Citations
19	No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone. Anti-Cancer Drugs, 2000, 11, 659-664.	1.4	21
20	Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 783-791.	3.3	21
21	Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. European Journal of Cancer, 1992, 28, 767-773.	2.8	18
22	KW-2149 (7-N-[2-[Y-L-glutamylamino]ethyldithioethyl]mitomycin C) a new mitomycin c analogue activated by serum. Biochemical Pharmacology, 1997, 53, 279-285.	4.4	14
23	Phagocytosis and lipofuscin accumulaton in lymph node macrophages. Mechanisms of Ageing and Development, 1986, 35, 161-167.	4.6	9
24	The Endothelium of the High Endothelial Venule: A Specialized Endothelium with Unique Properties. Pathobiology, 1987, 55, 1-10.	3.8	8
25	Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. British Journal of Cancer, 2017, 117, 195-202.	6.4	6
26	Mesenteric lymph nodes: cells with surface and sytoplasmic immunoglobulins. Vigiliae Christianae, 1984, 47, 123-129.	0.1	5
27	Flunarizine as a modulator of doxorubicin resistance in human colon-adenocarcinoma cells. International Journal of Cancer, 1993, 55, 636-639.	5.1	5
28	Isolation of high numbers of lymphoid cells from single lymph nodes from the rat. Journal of Immunological Methods, 1976, 12, 345-346.	1.4	3
29	New EORTC compounds. Cancer Treatment Reviews, 1990, 17, 119-125.	7.7	3
30	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. Npj Precision Oncology, 2021, 5, 96.	5.4	2
31	The role of pharmacology in anticancer drug development. ADMET and DMPK, 2018, 6, 4.	2.1	0